Alcidion signs contract with Leidos Australia

Melbourne, Australia – Alcidion Group Limited (ASX:ALC) today advises that it is a member of a consortium that has been awarded the contract to provide components of an enterprise Health IT Project for the Commonwealth of Australia .

The Consortium is led by Leidos Australia as the prime in a contract. Leidos (NYSE:LDOS) – parent company – is a global IT and engineering consulting firm. The Consortium involves several other digital health partners, many of them leading Australian providers, to deliver the full system requirements. More than 95% of the work will be delivered by Australian companies.

Alcidion will provide the Longitudinal Health Record via its Miya Precision product. The Miya Precision platform will aggregate data from Consortium partner solutions and other systems in the environment to establish a consolidated view of every participant health status and history.

The value of Alcidion’s contract is estimated to be $23.3M over six years. This will cover implementation and a subscription to the Miya Precision platform. Project commencement is planned for December 2021. Further options to take up Miya Observations and Assessments and options to renew up to 15 years creates a possible TCV for the contract with Leidos of around $50M.

The contract signing follows Alcidion’s announcement on 15 April 2021 announcing the company was selected as part of a consortium as the preferred vendor.

Managing Director and CEO Kate Quirke said: “Alcidion looks forward to working with Leidos and our Consortium partners to deliver this significant project. The scale and scope are a validation of Miya Precision’s existing capability to provide this critically important longitudinal health record”.


This announcement is authorised for release by the Board of Directors of Alcidion Group Limited.